Details for Patent: 7,459,466

Title:	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF.alpha. levels
Abstract:	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline- .
Inventor(s):	Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Filing Date:	Jan 14, 2005
Application Number:	11/035,817
Claims:	1. A compound of formula (I), or a salt or an optical isomer thereof: ##STR00006## 2. The compound of claim 1 having an optical purity of >95%. 3. An optical isomer of claim 1, which is (R)-3-(3-aminophthalimido)-3-methylpiperidine-2,6-dione or (S)-3-(3-aminophthalimido)-3-methylpiperidine-2,6-dione. 4. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the salt or the optical isomer of claim 1, and a pharmaceutically acceptable carrier, diluent or excipient. 5. The pharmaceutical composition of claim 4 wherein the therapeutically effective amount is for reducing levels of TNF.alpha., or treating inflammatory, autoimmune, oncogenic or cancerous disease in a mammal. 6. The pharmaceutical composition of claim 4, wherein said composition is in the form of a tablet, a capsule, a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel. 7. The pharmaceutical composition of claim 4, wherein said composition is suitable for oral, parenteral, topical, rectal, sublingual, buccal, vaginal, transdermal, or basal administration. 8. The pharmaceutical composition of claim 6, wherein said composition is in the form of a tablet. 9. The pharmaceutical composition of claim 6, wherein said composition is in the form of a capsule.